According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
A number of other analysts also recently weighed in on VBLT. Chardan Capital set a $20.00 price target on shares of Vascular Biogenics and gave the stock a buy rating in a report on Tuesday, November 29th. Roth Capital reaffirmed a buy rating and set a $17.00 price target on shares of Vascular Biogenics in a report on Thursday, December 1st. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $11.00 price target on shares of Vascular Biogenics in a report on Tuesday, February 21st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Vascular Biogenics currently has a consensus rating of Buy and a consensus target price of $12.90.
Vascular Biogenics (NASDAQ:VBLT) traded up 4.81% during midday trading on Friday, reaching $5.45. The company’s stock had a trading volume of 236,028 shares. The stock’s market capitalization is $146.62 million. The firm has a 50-day moving average price of $5.58 and a 200 day moving average price of $5.23. Vascular Biogenics has a 52-week low of $3.03 and a 52-week high of $7.58.
Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings data on Monday, March 27th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.01. Equities research analysts predict that Vascular Biogenics will post ($0.66) EPS for the current fiscal year.
An institutional investor recently raised its position in Vascular Biogenics stock. Menta Capital LLC increased its position in Vascular Biogenics Ltd (NASDAQ:VBLT) by 46.0% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 115,735 shares of the biopharmaceutical company’s stock after buying an additional 36,482 shares during the period. Menta Capital LLC owned approximately 0.43% of Vascular Biogenics worth $561,000 at the end of the most recent quarter. 14.95% of the stock is owned by institutional investors and hedge funds.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.